No Data
No Data
Express News | Shattuck Labs Inc : Citigroup Cuts Target Price to $10 From $11
TD Cowen Remains a Buy on Shattuck Labs (STTK)
Promising Clinical Trial Results Support a Buy Rating for Shattuck Labs
Express News | Shattuck Labs To Present Additional Data From Phase 1B Dose Expansion Trial Of SL-172154 Trial At EHA 2024 Congress Jun. 14
Express News | Shattuck Labs Inc - Sl-172154 Continued to Demonstrate an Acceptable Safety Profile in Combination With Aza
Shattuck Labs to Present Additional Data From the Phase 1B Dose Expansion Clinical Trial of SL-172154 With Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 Mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK) today announced the presentation of additional data from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in frontline HR-MDS and TP53m AML patients.